OrbiMed
Venture capital
Portfolio collected from the firm’s website, last checked Jul 26, 2026.Raises and exits come from each company’s own SEC and company records.
68Deep-tech portfolio39 active
29Portfolio exitsAcquired or listed
7Raises, 12 monthsLatest: Adela
53Co-investorsShare a portfolio company
Portfolio · 68 companies
| Company | Sector | Status | Latest raise | Raised |
|---|---|---|---|---|
| Adela | Medtech | Active | Oct 19, 2026 | $92.9M |
| Iambic Therapeutics | Biotech | Active | Sep 9, 2026 | $323.1M |
| Aer Therapeutics | Biotech | Active | Aug 19, 2026 | $23.9M |
| AirNexis Therapeutics | Biotech | Active | Mar 9, 2026 | $62.0M |
| Delfi Diagnostics | Medtech | Active | Dec 18, 2025 | $365.9M |
| Electra Therapeutics | Biotech | Active | Oct 30, 2025 | $134.2M |
| Avenzo Therapeutics | Biotech | Active | Sep 5, 2025 | $78.7M |
| Alpheus Medical | Biotech | Active | May 19, 2025 | $55.5M |
| Aerin Medical | Medtech | Active | Dec 30, 2024 | $140.8M |
| Convergent Therapeutics | Biotech | Active | Aug 13, 2024 | $51.4M |
| Brenig Therapeutics | Biotech | Active | Jul 30, 2024 | $30.0M |
| Evozyne | Biotech | Active | Sep 29, 2023 | $144.4M |
| ADARx Pharmaceuticals | Biotech | Active | Aug 10, 2023 | $352.5M |
| Gennao Bio | Biotech | Active | Dec 8, 2022 | $25.0M |
| Alterome Therapeutics | Biotech | Active | Jan 14, 2022 | $63.8M |
| Kumquat Biosciences | Biotech | Active | Aug 16, 2021 | $117.0M |
| Binx Health | Medtech | Active | Jun 11, 2021 | $103.6M |
| ForSight VISION6 | Medtech | Active | Sep 22, 2017 | $7.0M |
| Altis Labs | Biotech | Active | — | — |
| Appia Bio | Biotech | Active | — | — |
| ArCHitect Therapeutics | Biotech | Active | — | — |
| Arrowhead Pharmaceuticals | Biotech | Active | — | — |
| Aspen Neuroscience | Biotech | Active | — | — |
| Aviceda | Biotech | Active | — | — |
| Biobeat | Medtech | Active | — | — |
| Congruence Therapeutics | Biotech | Active | — | — |
| Curevo Vaccine | Biotech | Active | — | — |
| Eilean Therapeutics | Biotech | Active | — | — |
| Fore Bio | Medtech | Active | — | — |
| Forward Therapeutics | Biotech | Active | — | — |
| FUSmobile | Medtech | Active | — | — |
| Helicore Biopharma | Biotech | Active | — | — |
| iECURE | Biotech | Active | — | — |
| Kartos Therapeutics | Biotech | Active | — | — |
| Leal Therapeutics | Biotech | Active | — | — |
| Mendra | Biotech | Active | — | — |
| Nanotronics | Materials | Active | — | — |
| Ottimo Pharma | Biotech | Active | — | — |
| Structure Therapeutics | Biotech | Active | — | — |
| BlossomHill Therapeutics | Biotech | Public | Dec 10, 2025 | $245.8M |
| Olema Pharmaceuticals | Biotech | Public | Dec 12, 2024 | $503.5M |
| Candid Therapeutics | Biotech | Acquired | Sep 13, 2024 | $206.2M |
| Alumis | Biotech | Public | Jul 24, 2024 | $240.0M |
| Avalo Therapeutics | Biotech | Public | Apr 9, 2024 | $181.8M |
| EnLiven Therapeutics | Biotech | Public | Apr 3, 2024 | $140.1M |
| BioAge Labs | Biotech | Public | Feb 13, 2024 | $194.4M |
| CytomX Therapeutics | Biotech | Public | Aug 17, 2023 | $143.0M |
| Forte Biosciences | Biotech | Acquired | Aug 9, 2023 | $44.1M |
| MBX Biosciences | Biotech | Public | Nov 18, 2022 | $95.5M |
| ARS Pharmaceuticals | Medtech | Public | Sep 7, 2021 | $63.0M |
| Janux Therapeutics | Biotech | Public | Apr 30, 2021 | $192.4M |
| Aura Biosciences | Biotech | Public | Apr 6, 2021 | $178.7M |
| Edgewise Therapeutics | Biotech | Public | Dec 10, 2020 | $120.1M |
| Compass Therapeutics | Biotech | Public | Jul 1, 2020 | $255.8M |
| Keros Therapeutics | Biotech | Public | Mar 12, 2020 | $70.8M |
| Avitide | Biotech | Acquired | Oct 23, 2019 | $40.9M |
| Adicet Bio | Biotech | Public | Oct 9, 2019 | $105.9M |
| Myriad Genetics | Biotech | Public | Feb 12, 2019 | — |
| Emergent BioSolutions | Biotech | Public | Oct 30, 2018 | $47.9M |
| Prevail Therapeutics | Biotech | Acquired | Mar 14, 2018 | $57.0M |
| Guardant Health | Biotech | Public | Aug 9, 2017 | $500.0M |
| Corvus Pharmaceuticals | Biotech | Public | Sep 25, 2015 | $87.7M |
| Braveheart Bio | Biotech | Public | — | — |
| Chemomab | Biotech | Public | — | — |
| Cullinan Therapeutics | Biotech | Public | — | — |
| Lomond Therapeutics | Biotech | Acquired | — | — |
| MDxHealth | Medtech | Public | — | — |
| Merus | Biotech | Acquired | — | — |
Peer ranks
Portfolio size#4
Portfolio exits#3
Raises, 12 months#2
Co-investors#26
Co-investors
- RA CapitalVenture capital6 shared
- Frazier Healthcare PartnersVenture capital4 shared
- Lilly VenturesVenture capital3 shared
- ARCH VentureVenture capital2 shared
- EcoR1 CapitalVenture capital2 shared
- Enavate SciencesVenture capital2 shared
- Khosla VenturesVenture capital2 shared
- MedicxiVenture capital2 shared
- Omega FundsVenture capital2 shared
- Sands Capital VenturesVenture capital2 shared
Sectors
- Biotech57
- Medtech10
- Materials1
Portfolios are collected from investors’ own websites and matched to tracked deep-tech companies by name; duplicate listings of the same firm are merged. Exits and raises come from each company’s own record: Form D through the latest filing.